Following the Centers for Medicare & Medicaid Services (CMS) announcement on the possible integration of CBD products into federally approved healthcare models, speculation has increased about the future of the US wellness landscape. Initiatives are being introduced to allow participating healthcare providers to distribute up to USD $500 worth of cannabinoid products to eligible Medicare patients under the Substance Access Beneficiary Engagement Incentive (BEI).
BEI is a structured system designed to evaluate how hemp-derived products may help patients manage chronic or complex conditions. This program does not operate through a direct billing system. Instead, it allows eligible provider groups to furnish appropriate CBD products to qualified patients, provided they properly implement the program.
Like many others, you may also be wondering: how does the Medicare CBD program work? To understand this, you need to familiarize yourself with the various components of this pilot program.
Substance Access Beneficiary Engagement Incentive
Healthcare organizations can choose to support BEI if they already participate in a CMS care model. It allows them to help eligible Medicare patients use prescribed CBD products for their symptoms. Its funding structure differs significantly from that of traditional insurance claims. Neither you nor your provider receives reimbursement for these products. As a result, you do not need to submit any claims. If your organization elects BEI benefits, it can offer CBD guidance and products as part of its care plans. This is not considered a violation of Medicare billing protocols.
CMS care models
You do not qualify for Medicare CBD benefits simply because you are an enrollee. As mentioned earlier, your healthcare provider must be part of one of the three CMS care models.
- Enhancing Oncology Model: This model focuses on improving outcomes for cancer patients. It supports oncology practices in providing coordinated, patient-centered care to individuals undergoing chemotherapy. Many of these patients may need alternative solutions to manage nausea and pain. Under BEI, they may be able to access CBD benefits starting April 1, 2026.
- ACO REACH Model: Under this model, doctors, hospitals, and other healthcare providers collaborate to help Medicare patients access high-quality care.
- Long-term Enhanced ACO Design Model: This program focuses on independent providers and practices that care for high-needs patients. Many of these patients may be enrolled in both Medicare and Medicaid.
Patients’ eligibility
The facility where you receive treatment may have elected the CBD benefit and may participate in one of the primary CMS care models. However, this alone does not make you eligible for coverage. You must meet certain clinical requirements to receive CBD products at no cost, up to the fixed annual limit. Eligibility starts with age—you must be at least 18 years old. Individuals who are pregnant or breastfeeding are excluded from the program. Your doctor must confirm that CBD products are appropriate for your medical condition. You should also understand the potential risks and benefits of incorporating them into your regular care routine.
CBD products must also comply with CMS regulations and federal guidelines. Oral solutions, such as gummies and tinctures, may be covered by Medicare if they meet all THC-related limitations. They must also be lab-tested and of high quality.
